HC Wainwright initiated coverage on shares of Adlai Nortye (NASDAQ:ANL – Free Report) in a research report report published on Wednesday, Marketbeat.com reports. The brokerage issued a buy rating and a $9.00 price objective on the stock. HC Wainwright also issued estimates for Adlai Nortye’s FY2024 earnings at ($0.88) EPS, FY2025 earnings at ($0.92) EPS and FY2026 earnings at ($0.99) EPS.
Separately, Cantor Fitzgerald reaffirmed an overweight rating on shares of Adlai Nortye in a research note on Thursday, June 20th.
Get Our Latest Research Report on Adlai Nortye
Adlai Nortye Trading Down 7.2 %
Institutional Inflows and Outflows
An institutional investor recently raised its position in Adlai Nortye stock. Cantor Fitzgerald L. P. grew its position in shares of Adlai Nortye Ltd. (NASDAQ:ANL – Free Report) by 128.2% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 40,310 shares of the company’s stock after acquiring an additional 22,644 shares during the period. Cantor Fitzgerald L. P. owned about 0.11% of Adlai Nortye worth $362,000 at the end of the most recent quarter. Institutional investors and hedge funds own 35.21% of the company’s stock.
About Adlai Nortye
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.
See Also
- Five stocks we like better than Adlai Nortye
- What Does a Stock Split Mean?
- Is Merck Stock Undervalued After Its Colossal Earnings Growth?
- How to Buy Cheap Stocks Step by Step
- Top 5 ETFs for Every Investor: From Semiconductors to Defense
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Blade Air Mobility: This Under-the-Radar Stock Could Double Soon
Receive News & Ratings for Adlai Nortye Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adlai Nortye and related companies with MarketBeat.com's FREE daily email newsletter.